Yahoo Finance 
The Global Non-melanoma Skin Cancer Market is expected to grow by $ 180.97 million during 2022-2026, accelerating at a CAGR of 5.76% during the forecast period
Global Non-melanoma Skin Cancer Market 2022-2026 The analyst has been monitoring the non-melanoma skin cancer market and it is poised to grow by $ 180. 97 million during 2022-2026, accelerating at a CAGR of 5.
New York, May 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-melanoma Skin Cancer Market 2022-2026" - https://www.reportlinker.com/p05691253/?utm_source=GNW
76% during the forecast period. Our report on the non-melanoma skin cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by NMSC coverage and support, increase in awareness about skin cancer, and initiatives by organizations.
The non-melanoma skin cancer market analysis includes the type segment and geographic landscape.
The non-melanoma skin cancer market is segmented as below:
By Type
• BCC
• SCC
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the increasing incidence of NMSC as one of the prime reasons driving the non-melanoma skin cancer market growth during the next few years. Also, the consideration of surgery as the first-line curative approach for NMSC and high off-label use of topical treatments for NMSC will lead to sizable demand in the market.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on non-melanoma skin cancer market covers the following areas:
• Non-melanoma skin cancer market sizing
• Non-melanoma skin cancer market forecast
• Non-melanoma skin cancer market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-melanoma skin cancer market vendors that include 3M Corp., Almirall SA, Amgen Inc., Bausch Health Companies Inc., Bristol Myers Squibb Co., Elekta AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, iCAD Inc., Merck and Co. Inc., Mylan N.V, Novartis AG, Pfizer Inc., Sensus Healthcare Inc., Sun Pharmaceutical Industries Ltd., Varian Medical Systems Inc., and Vidac Pharma. Also, the non-melanoma skin cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Read the full report: https://www.reportlinker.com/p05691253/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
